Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2011

View Archived Issues

Combination of HER2 and VEGF peptidomimetics block angiogenesis and tumor cell growth

Atsttrin suppresses onset and symptoms of inflammatory arthritis in vivo

Immunohistochemical quantitation of LAMP-2 for the diagnosis of phospholipidosis

Superoxide dismutase [Cu-Zn] as a biomarker for drug-induced liver injury

Novel fluoroquinolone antibacterial agents patented by Achaogen

BioCryst presents new tyrosine-protein kinase JAK3 inhibitors

Novel HSP 90 inhibitors synthesized at Nerviano Medical Sciences

New inhibitors of dual specificity protein kinase TTK presented

Concert Pharma presents new deuterated xanthine derivatives

Dipraglurant enters phase IIa trial in Parkinson's disease and levodopa-induced dyskinesia

BARDA funds development of influenza therapy CS-8958

Metabolic Solutions Development begins phase IIa trial of MSDC-0602

Intercept Pharma reports phase II data on obeticholic acid in primary biliary cirrhosis

Polaris Pharma begins pivotal studies of ADI-PEG 20

Solvay to launch offer for Rhodia

MP-29-02 NDA filed in U.S. for seasonal allergic rhinitis

Eisai and PRISM collaborate on inhibitors of complex between CREB-binding protein and catenin beta-1

Ongoing phase II proof-of-concept trial evaluates LY-2828360 for osteoarthritic knee pain

IPI-926 reduces tumor growth in vivo and advances through clinical development

Lundbeck launches Sycrest in first European market

Algeta and Genzyme to collaborate on new approach to cancer treatment

QIAGEN reaches agreement to acquire Cellestis

Generex presents new strategic development plan

Anavex Life Sciences begins screening for phase I study of ANAVEX 2-73

Furiex Pharma evaluates PPD-10558 in phase II study in subjects with statin intolerance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...